MRMD Archives - Channelchek

Release – MariMed Promotes Ryan Crandall to Chief Commercial Officer

Posted on April 7, 2025April 7, 2025 by aweinsoff@channelchek.com

April 07, 2025 7:30am EDT

NORWOOD, Mass., April 07, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer has promoted Ryan Crandall to Chief Commercial Officer, effective immediately. In his new role, Mr. Crandall will lead the Company’s commercial strategy and activities, including Sales, Marketing, Product Development, and Retail Operations. He has served as MariMed’s Chief Revenue Officer since July 2022, and prior was the Company’s Chief Products Officer and SVP, Sales for four years. Mr. Crandall will continue to report to MariMed CEO Jon Levine.

“Ryan has been a driving force behind creating our innovative and trusted portfolio of brands and establishing them as top sellers in our core markets,” said Mr. Levine. “He has also guided our efforts to deliver an exceptional customer experience at our retail locations. His promotion to Chief Commercial Officer is well-deserved and I look forward to his continued contributions to value generation for our customers and shareholders.”

Mr. Crandall entered the cannabis industry in 2014 when he co-created Betty’s Eddies™, a brand of all-natural, cannabis-infused chews that MariMed acquired prior to his joining the company in 2018. Prior, he held a series of executive positions with increasing sales responsibilities in major cybersecurity and software corporations, including RSA Security and EMC2.

“I am honored and excited to step into the role of Chief Commercial Officer at MariMed,” said Mr. Crandall. “Being a part of this great company, with its award-winning brands, dedication to strategic growth initiatives, and commitment to its mission of improving lives, has been a fantastic journey. I’m eager to deepen my collaboration with our talented team, building on our collective success to strengthen MariMed’s position as a leading cannabis products company.”

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, InHouse™, Nature’s Heritage™, and Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Source: MariMed Inc.

Released April 7, 2025

Release – MariMed’s Betty’s Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel Chews

Posted on April 3, 2025April 3, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MRMD

April 03, 2025 7:30am EDT

Each Betty’s Caramelt Away Chew Uses Rich, Buttery Caramel, To Create Moments of Mellow

NORWOOD, Mass., April 03, 2025 (GLOBE NEWSWIRE) — Betty’s Eddies™, the all-natural cannabis chews handcrafted to fit a variety of needs, is expanding its lineup with the introduction of delicious caramel chews: Betty’s Caramelt Away. Betty’s Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD).

Debuting in time for National Caramel Day on April 5, Betty’s Caramelt Away chews are now available at select cannabis retailers throughout Massachusetts, with plans for expansion into MariMed’s wholesale markets in the future. Each chew wraps customers in warmth with the rich, comforting flavor of classic caramel. They’re infused with a soothing blend of full-spectrum hash and CBG that lets consumers sink into sweet, cozy melty moments of mellow.

“Betty’s Eddies and caramel is the perfect pairing of two fan favorites,” said Sara Rosenfield, Brand Director at MariMed for Betty’s Eddies. Betty’s Eddies is the most popular edible brand in several of our core markets: Massachusetts, Maryland, and Delaware. Caramel consistently ranks among the most popular ingredients in candy and other sweet treats. Cannabis consumers will love the full-flavor, full-spectrum experience that the brand is known for with the creamy deliciousness of caramel.”

Betty’s Caramelt Away joins a full slate of Betty’s Eddies products that feature specific end-effects, including Bedtime Betty’s for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Smashin’ Passion for sexual wellness, and Betty Good Times for any time.

About Betty’s Eddies
Betty’s Eddies™ all-natural fruit chews are handcrafted with full-spectrum cannabis, supporting cannabinoids, and herbal supplements and vitamins. Designed for whatever life throws at you, varieties include pain relief, immunity, energy, sleep and more. Founded in 2014 by medical cannabis patients on a mission to craft the best tasting and most effective edibles, best-selling Betty’s Eddies encompass the full spectrum of the plant’s benefits, including natural adaptogens, and are handcrafted in small batches with real organic fruits and vegetables. Find Betty’s Eddies in licensed dispensaries in Delaware, Maryland, Massachusetts, and Missouri. Learn more at www.bettyseddies.com.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Source: MariMed Inc.

Released April 3, 2025

MariMed Inc. (MRMD) – A Cannabis Brands Company; Initiating Coverage

Posted on April 3, 2025April 3, 2025 by cpereira@noblefcm.com

Thursday, April 03, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating Research Coverage. We are initiating research coverage of MariMed, Inc. with an Outperform rating and a $0.25 price target. MariMed is a cannabis brand powerhouse, in our view, with leading market shares in current markets and significant expansion potential both within existing markets and new greenfield markets.

MSO. With operations in six states, MariMed is a vertically integrated seed-to-sale cannabis provider. Following in the footsteps of successful consumer brands companies, MariMed has three market leading brands across its operations. We expect the Company to benefit from the growth of its brands in growing markets as well as the addition of new markets in Ohio, Illinois, and Delaware in 2025.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.